dc.creatorShiffer, Dana
dc.creatorZamunér, Antonio
dc.creatorMinonzio, Maura
dc.creatorBulgheroni, Mara
dc.creatorPorta, Alberto
dc.creatorLeone, Roberto
dc.creatorBottazzi, Barbara
dc.creatorGarlanda, Cecilia
dc.creatorColotta, Francesco
dc.creatorBarbic, Franca
dc.creatorMantovani, Alberto
dc.creatorFurlan, Raffaello
dc.date2023-10-10T18:36:55Z
dc.date2023-10-10T18:36:55Z
dc.date2023
dc.date.accessioned2024-05-02T20:31:43Z
dc.date.available2024-05-02T20:31:43Z
dc.identifierhttp://repositorio.ucm.cl/handle/ucm/5002
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9275219
dc.descriptionIntroduction: Systemic inflammation promotes neurodegeneration in Parkinson’s disease (PD). Interleukin-1 receptor type 2 (sIL-1R2) plasma levels increase during inflammation. Data on sIL-1R2 in PD patients and its relationship with PD cardiac autonomic profile are limited, given the possible anti-inflammatory effect of vagal activation. Previously, automated mechanical peripheral somatosensory stimulation (AMPSS) enhanced cardiac vagal modulation. Objectives were to 1) evaluate sIL-1R2 plasma concentrations in PD patients and healthy controls and 2) investigate the correlations between sIL-1R2 and cardiac autonomic indices obtained by spectrum analysis of heart rate variability before and after AMPSS. Methods: sIL-1R2 plasma levels were assessed in 48 PD patients and 50 healthy controls. Electrocardiogram and beat-by-beat arterial pressure were recorded at baseline and after 5 AMPSS sessions in 16 PD patients. Results: PD patients had higher sIL-1R2 levels than controls. In the PD subgroup, an inverse correlation between sIL-1R2 and HFnu was found. There was a negative correlation between changes induced by AMPSS on HFnu and sIL-1R2. Discussion: Higher sIL-1R2 levels in PD patients reflect the inflammatory dysregulation associated with the disease. In PD patients, higher sIL-1R2 was associated with reduced cardiovagal tone. Increased cardiovagal modulation following AMPSS was associated with lower sIL-1R2 levels in Parkinson’s disease patients, suggesting inflammatory state improvement.
dc.languageen
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.sourceFrontiers in Physiology, 14, 1168652
dc.subjectSoluble interleukin-1 receptor type 2 (sIL-1R2)
dc.subjectCardiovascular autonomic control
dc.subjectParkinson’s disease
dc.subjectMechanical somatosensory stimulation
dc.subjectHeart rate variability
dc.titleSoluble interleukin-1 receptor type 2 plasma levels in Parkinson’s disease: relationship with cardiac autonomic profile before and after peripheral mechanical somatosensory stimulation
dc.typeArticle


Este ítem pertenece a la siguiente institución